Printer Friendly

CEL-SCI WINS FINAL ROUND IN EUROPEAN PATENT LITIGATION

 CEL-SCI WINS FINAL ROUND IN EUROPEAN PATENT LITIGATION
 ALEXANDRIA, Va., Aug. 20 /PRNewswire/ -- CEL-SCI Corporation (NASDAQ: CELI) announced that it was successful in defending an important European patent. The patent, no. 0049611, covers CEL-SCI's proprietary cytokine mixture product "BC-IL" and method for producing same. This ends several years of litigation between Biotest Pharma GmbH of Germany, one of the major producers of blood-derived products in Europe, and CEL-SCI Corporation.
 Several years ago Biotest Pharma filed an opposition aimed at voiding the European patent in question. In fall of 1990, the European Patent Office Opposition Division rejected Biotest Pharma's annulment suit and ruled for CEL-SCI Corporation. Biotest Pharma then appealed the case to the Appeals Board of the European Patent Office, which has now maintained the patent with all the process claims, which also protect the products of the claimed process. Thus, the patent continues to provide CEL-SCI Corporation with very valuable protection.
 Maximilian de Clara, president of CEL-SCI Corporation, said: "Patent protection is the key to success in the pharmaceutical business. Not having it is tantamount to exclusion from the market place no matter how much good work a company has done in the lab and clinic. The European decision significantly strengthens our position."
 CEL-SCI Corporation has pioneered the development of combination therapy using "natural" lymphokine and cytokine mixtures ("cocktails") for the treatment of cancers and immunodeficiencies. Its 50 percent-owned subsidiary, Viral Technologies, Inc., is developing the HGP-30 AIDS vaccine/treatment based on a piece of the p17 core protein.
 -0- 8/20/92
 /CONTACT: Matt Haines of Strategic Growth International, 212-826-9622, or Daryll Strahl, 303-979-5735, both for CEL-SCI/
 (CELI) CO: CEL-SCI Corporation ST: Virginia IN: MTC SU:


TW -- DC001 -- 1577 08/20/92 08:31 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 20, 1992
Words:287
Previous Article:A.M. BEST SPONSORS CONFERENCE IN BALTIMORE
Next Article:WILLIS CORROON GROUP plc REPORTS RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 1992
Topics:


Related Articles
CEL-SCI CORPORATION TECHNOLOGY PROTECTED BY NEW JAPANESE PATENT
CEL-SCI GETS NEW STOCK SYMBOL FOR 30 DAYS
CEL-SCI ENTERS INTO AGREEMENT TO GAIN 100% OWNERSHIP OF AIDS TECHNOLOGY
CEL-SCI CORPORATION FILES CONTRACT BREACH AND PATENT INFRINGEMENT LAWSUITAGAINST IMMUNORX AND DR. JOHN HADDEN, A FORMER COLLABORATOR
CEL-SCI Raises $5.0 Million
CEL-SCI Corporation Extends Warrant Date
Key Product Patent for CEL-SCI Issued By Japanese Patent Office
CEL-SCI Corporation Announces Development of a Potential AIDS Vaccine For Worldwide Use
CEL-SCI Corporation Announces New Address and Phone Number
CEL-SCI Corporation Starts Phase II Trial with HGP-30W AIDS Vaccine

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters